Boehringer Ingelheim Extends TrialScope Partnership


July 6, 2020

Jersey City, NJ, July 7, 2020 — In its ongoing commitment to maintaining compliance with ever-changing global clinical trial disclosure regulations, Boehringer Ingelheim has renewed its partnership with TrialScope for an additional five years. More specifically, the company has renewed its license for use of the TrialScope DiscloseTM platform.

TrialScope is the global leader in clinical trial transparency, with 16 of the top 20 industry sponsors relying on TrialScope technology for trial disclosure management. Collectively, TrialScope customers are responsible for more than 40 percent of all industry trials on and the EU-CTR.

A TrialScope customer since 2015, Boehringer Ingelheim has several hundreds of studies managed with the TrialScope Disclose platform.

“We are proud to partner with Boehringer Ingelheim, a company that makes its commitment to clinical trial transparency a top priority.” said Francine Lane, TrialScope Vice President for Global Transparency. “That commitment, as proven by its remarkable disclosure compliance, is a reflection of the value the company places on improving the health and quality of life of those impacted by its research. We look forward to helping foster even greater long-term success for Boehringer Ingelheim.”

For more information on TrialScope or TrialScope Disclose™, visit

About TrialScope 

TrialScope unlocks clinical trial data superpowers. The TrialScope Transparency CloudTM makes centralizing, structuring and activating clinical trial information simple, for use across the organization and at every stage of the study. Our integrated platform is used by 16 of the top 20 clinical trial sponsors in the world, who rely on TrialScope to ensure disclosure compliance, maximize trial transparency, improve patient engagement and accelerate study recruitment. To learn more, visit

About Boehringer Ingelheim

Information about Boehringer Ingelheim can be found on  or in the annual report: